Ankyra closes $45M funding round

By The Science Advisory Board staff writers

November 12, 2021 -- Ankyra Therapeutics recently closed on $45 million in series B financing that will help advance the company's lead molecule ANK-101.

Several new investors joined in the funding, including Borealis Ventures, Fidelity Management & Research Company, GV, Sands Capital Ventures, and Spring Mountain Capital. Existing investors include Polaris Partners and Mithril Capital. Phil Ferneau of Borealis Ventures will join the Ankyra Therapeutics' board of directors.

The funding will allow for new studies and phase I clinical trials, as well as advance additional cytokine programs, the company said.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.